Significant Decline in HCV-Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015–2022): A Sentinel Center Study

IF 5.2 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver International Pub Date : 2025-10-07 DOI:10.1111/liv.70388

Cheng-Yeh Yang, Chih-Yun Lin, Jing-Houng Wang, Chun-Yen Lin, Rong-Nan Chien, Sheng-Nan Lu

{"title":"Significant Decline in HCV-Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015–2022): A Sentinel Center Study","authors":"Cheng-Yeh Yang, Chih-Yun Lin, Jing-Houng Wang, Chun-Yen Lin, Rong-Nan Chien, Sheng-Nan Lu","doi":"10.1111/liv.70388","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Reducing mortality attributable to hepatitis C virus (HCV) is a key target in the World Health Organization (WHO) HCV elimination strategy. While liver cancer registration in Taiwan includes hepatitis C antibody (anti-HCV) status, no national registry records viral etiologies for deaths from liver cirrhosis and chronic liver disease (LC/CLD). Therefore, this sentinel study aimed to estimate national trends in HCV-related LC/CLD mortality.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study period spanned from 2015 to 2022. According to ICD-10 codes K70, K73 and K74, the annual mortality numbers for LC/CLD were extracted from national biostatistics. Using the Chang Gung Research Database (CGRD), cases that died from LC/CLD with available results for both HBsAg and anti-HCV tests were included in the analysis. Based on the proportions of HCV distributions from CGRD, the national viral etiology-specific case numbers were estimated using a direct standardised method.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 35 413 patients died from LC/CLD nationally, with 15 445 of them having medical records in CGRD, and 5940 (16.8%) having results for both HBsAg and anti-HCV tests. The national case number was 4878 in 2015, decreasing to 4107 (−15.8%) in 2022. The proportion of anti-HCV decreased from 25.7% to 16.6% (−36.2%). Direct standardisation showed that the estimated national case number for anti-HCV decreased from 1424 to 811 (−43%).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>From 2015 to 2022, Taiwan experienced a 43% decline in HCV-related LC/CLD mortality, supporting progress toward national HCV elimination goals.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502887/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.70388","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Reducing mortality attributable to hepatitis C virus (HCV) is a key target in the World Health Organization (WHO) HCV elimination strategy. While liver cancer registration in Taiwan includes hepatitis C antibody (anti-HCV) status, no national registry records viral etiologies for deaths from liver cirrhosis and chronic liver disease (LC/CLD). Therefore, this sentinel study aimed to estimate national trends in HCV-related LC/CLD mortality.

Methods

The study period spanned from 2015 to 2022. According to ICD-10 codes K70, K73 and K74, the annual mortality numbers for LC/CLD were extracted from national biostatistics. Using the Chang Gung Research Database (CGRD), cases that died from LC/CLD with available results for both HBsAg and anti-HCV tests were included in the analysis. Based on the proportions of HCV distributions from CGRD, the national viral etiology-specific case numbers were estimated using a direct standardised method.

Results

A total of 35 413 patients died from LC/CLD nationally, with 15 445 of them having medical records in CGRD, and 5940 (16.8%) having results for both HBsAg and anti-HCV tests. The national case number was 4878 in 2015, decreasing to 4107 (−15.8%) in 2022. The proportion of anti-HCV decreased from 25.7% to 16.6% (−36.2%). Direct standardisation showed that the estimated national case number for anti-HCV decreased from 1424 to 811 (−43%).

Conclusions

From 2015 to 2022, Taiwan experienced a 43% decline in HCV-related LC/CLD mortality, supporting progress toward national HCV elimination goals.

Abstract Image

查看原文本刊更多论文

肝硬化和慢性肝病hcv相关死亡率显著下降（2015-2022）：一项前哨中心研究

背景：降低丙型肝炎病毒（HCV）的死亡率是世界卫生组织（WHO）消除丙型肝炎病毒战略的一个关键目标。虽然台湾的肝癌登记包括丙型肝炎抗体（抗hcv）状态，但没有全国性登记记录肝硬化和慢性肝病（LC/CLD）死亡的病毒病因。因此，这项哨点研究旨在估计hcv相关LC/CLD死亡率的全国趋势。方法：研究时间为2015 - 2022年。根据ICD-10编码K70、K73和K74，从国家生物统计数据中提取LC/CLD的年死亡率数字。使用常庚研究数据库（CGRD），分析包括HBsAg和抗- hcv检测结果均可用的LC/CLD死亡病例。根据来自CGRD的HCV分布比例，使用直接标准化方法估计全国病毒病原学特异性病例数。结果：全国共有35413例患者死于LC/CLD，其中15445例在CGRD有医疗记录，5940例（16.8%）同时有HBsAg和anti-HCV检测结果。2015年全国病例数为4878例，2022年下降至4107例（-15.8%）。抗- hcv比例由25.7%降至16.6%（-36.2%）。直接标准化显示，全国抗丙肝病毒病例数估计数从1424例下降到811例（-43%）。结论：从2015年到2022年，台湾HCV相关的LC/CLD死亡率下降了43%，支持了国家消除HCV目标的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver International 医学-胃肠肝病学

CiteScore

13.90

自引率

4.50%

发文量

348

审稿时长

2 months

期刊介绍： Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.